The Federal Trade Commission filed a lawsuit to prevent Edward LifeSciences from acquiring JenaValve Technology, arguing the deal would stifle innovation in treatments for aortic regurgitation, a serious heart condition in which blood leaks in the heart chamber, Bloomberg reported Aug. 6.
The complaint, filed in U.S. District Court for the District of Columbia, alleges the merger would reduce competition in a market where few treatment options exist.
JenaValve’s device has received approval for use in the European Union and is expected to be cleared by the FDA later in 2025, the report said. Despite the lawsuit, Edward LifeSciences said it intends to pursue the acquisition, arguing the deal would help the devicemakers’ innovation footprint and improve access to treatments.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
